Related references
Note: Only part of the references are listed.Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial
Josef S. Smolen et al.
RHEUMATOLOGY (2021)
Factors Influencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab Biosimilar
Jocelyn Courville et al.
BIODRUGS (2021)
Real-world experience of effectiveness of non-medical switch from originator to biosimilar rituximab in rheumatoid arthritis
Andrew R. Melville et al.
RHEUMATOLOGY (2021)
First exposure to rituximab is associated to high rate of anti-drug antibodies in systemic lupus erythematosus but not in ANCA-associated vasculitis
Francesca Faustini et al.
ARTHRITIS RESEARCH & THERAPY (2021)
Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: ofatumumab as alternative therapy
Alice Combier et al.
RHEUMATOLOGY (2020)
Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study
Muriel Elhai et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial
Seung Cheol Shim et al.
RHEUMATOLOGY (2019)
Brief Report: Safety and Immunogenicity of Rituximab Biosimilar GP 2013 After Switch From Reference Rituximab in Patients With Active Rheumatoid Arthritis
Hans-Peter Tony et al.
ARTHRITIS CARE & RESEARCH (2019)
Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies
Nicky Dunn et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies
Nicky Dunn et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: A 12-year longitudinal multi-center study
G. Boleto et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2018)
CT-P13: design, development, and place in therapy
Tommaso Gabbani et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2017)
Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study
Wojciech Jurczak et al.
LANCET HAEMATOLOGY (2017)
A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Physicochemical and Functional Comparability Between the Proposed Biosimilar Rituximab GP2013 and Originator Rituximab
Jan Visser et al.
BIODRUGS (2013)
Safety of rituximab in rheumatoid arthritis: A long-term prospective single-center study of gammaglobulin concentrations and infections
Anne Isvy et al.
JOINT BONE SPINE (2012)
Efficacy and Safety of Retreatment in Patients with Rheumatoid Arthritis with Previous Inadequate Response to Tumor Necrosis Factor Inhibitors: Results from the SUNRISE Trial
Philip J. Mease et al.
JOURNAL OF RHEUMATOLOGY (2010)
Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)
Andrea Rubbert-Roth et al.
RHEUMATOLOGY (2010)
Share Paper
